Hormone Replacement Therapy Monitoring

Introduction to HRT Monitoring

• For central hypogonadism and thyroid hormone replacement, hormone levels should be monitored regularly, with re-evaluation in 2-3 months for central hypogonadism and annually for thyroid hormone replacement, or sooner if the patient's status changes, as recommended by the Endocrine Society 1
• Women with premature ovarian insufficiency (POI) using HRT should have a clinical review annually, with particular attention to compliance, according to the European Society of Human Reproduction and Embryology 2

Monitoring Frequency

• For hypothyroidism, TSH and free T4 testing should be repeated after 6-8 weeks, and if TSH remains above the reference range, the thyroid hormone dose should be increased by 12.5-25 mcg, as suggested by the American Thyroid Association 1
• If androgen therapy is commenced, the treatment effect should be evaluated after 3-6 months, according to the International Society for the Study of Women's Sexual Health 2

Dose Adjustments

• For thyroid hormone replacement, the dose should be adjusted based on TSH and free T4 levels, with a goal of achieving optimal clinical benefit while minimizing risks, as recommended by the American Association of Clinical Endocrinologists 1
• The thyroid hormone dose should be increased by 12.5-25 mcg if TSH remains above the reference range, as suggested by the American Thyroid Association 1
• Dose adjustments should be made by increasing the dose by 12.5-25 mcg increments every 4-6 weeks until a euthyroid state is achieved, with consideration for a more gradual dose increase of 12.5 mcg in patients with coronary artery disease or elderly patients 3, 4

Special Considerations

• Bile acid sequestrants, such as cholestyramine, colestipol, and colesevelam, can reduce levothyroxine absorption by binding to it in the GI tract, and administration of levothyroxine should be spaced out from these medications, with a recommended 3-hour window between administration based on gastric emptying studies 5
• Rifamycins, such as rifampin, can increase levothyroxine clearance, requiring dose increases in patients with hypothyroidism, according to the American Journal of Respiratory and Critical Care Medicine and Clinical Infectious Diseases society 6, 7, 8
• Levothyroxine should be taken on an empty stomach, 30-60 minutes before breakfast, and separate from medications that interfere with absorption, such as calcium, iron supplements, and antacids, with a recommended separation of at least 4 hours from most interacting medications 3
• The American Medical Association recommends a target TSH range of 0.5-4.5 mIU/L for patients with hypothyroidism, and TSH levels persistently above 10 mIU/L warrant dose adjustment, with a recommended increase of 25 mcg to achieve a daily dose of 125 mcg for most adult patients, except for elderly patients (>70 years) who may require a lower starting dose of 25-50 mcg/day 3, 4
• Elderly patients are more sensitive to thyroid hormone and at higher risk for cardiac complications, and should be considered for a more conservative dose increase of 12.5 mcg, with monitoring for symptoms of cardiac stress, such as palpitations, chest pain, and increased angina 3, 4

Follow-up and Monitoring

• Levothyroxine takes approximately 6-8 weeks to optimize thyroid hormone levels, at which point TSH and free T4 should be measured to assess adequacy of replacement and make dose adjustments as needed 1, 4, 3
• After starting levothyroxine, wait 6-8 weeks before checking thyroid function tests, and once TSH normalizes, patients should be monitored every 6-12 months, with consideration for more frequent monitoring in patients with coronary artery disease or elderly patients 1, 4, 3
• When evaluating thyroid function, always check both TSH and free T4, as central hypothyroidism may present with normal or low TSH, and compliance issues should be addressed before increasing the dose 3, 4